Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoChange Detected- New timestamps were added to the Study Record Dates to reflect the most recent maintenance events (QC submission and posting). These entries update the record's activity timeline.SummaryDifference0.2%

- Check10 days agoChange DetectedThe study's Locations section was updated to reflect 39 participating sites, replacing the previous larger roster and changing the geographic mix of sites.SummaryDifference3%

- Check18 days agoChange DetectedUpdated the displayed revision/version from **v3.5.0** to **v3.5.2**.SummaryDifference0.0%

- Check39 days agoChange DetectedThe study record history was updated with new entries on 2026-03-27 and 2026-03-30. Earlier updates from 2026-03-06 and 2026-03-09 were removed.SummaryDifference0.1%

- Check47 days agoChange DetectedRevision tag updated to v3.5.0 and the previous tag v3.4.3 was removed.SummaryDifference0.0%

- Check54 days agoChange DetectedThe study locations list was updated to reflect 56 sites, with additions across multiple countries and removals of several previously listed sites.SummaryDifference3%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.